Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alpha Tau Medical Ltd. - Ordinary Shares (NQ:DRTS)

2.910 -0.050 (-1.69%)
Streaming Delayed Price Updated: 3:57 PM EDT, Jun 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23,514
Open 2.940
Bid (Size) 2.910 (7)
Ask (Size) 2.950 (1)
Prev. Close 2.960
Today's Range 2.900 - 3.070
52wk Range 1.750 - 4.387
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alpha Tau Stock Rallies To 3-Month High On Smaller-Than-Feared Q1 Loss: Retail Sentiment Stays Bearish
The company’s stock surged to a three-month high following its Q1 report, progress in FDA-approved clinical trials, and a recent capital raise. 
Via Stocktwits
Exposures Product Safety
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
Investment comes at a pivotal moment for Alpha Tau, which is experiencing remarkable growth on multiple fronts, with four active U.S. trial approvals, expansion into multiple internal organ... 
From Alpha Tau Medical Ltd.
Via GlobeNewswire

Performance

YTD
-6.1%
-6.1%
1 Month
-6.1%
-6.1%
3 Month
+11.9%
+11.9%
6 Month
-8.5%
-8.5%
1 Year
+30.5%
+30.5%

More News

Read More
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Expert Ratings for Alpha Tau Medical
Via Benzinga
Analyst Ratings for Alpha Tau Medical
Via Benzinga
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
Via ACCESS Newswire
Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Treats First Patient with Recurrent Lung Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
From Alpha Tau Medical Ltd.
Via GlobeNewswire
DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q2 2024
Via InvestorPlace
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
From Alpha Tau Medical Ltd.
Via GlobeNewswire
DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q1 2024
Via InvestorPlace
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
DRTS Stock Earnings: Alpha Tau Medical Beats EPS for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
From Alpha Tau Medical Ltd.
Via GlobeNewswire
Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
From Alpha Tau Medical Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga

Frequently Asked Questions

Is Alpha Tau Medical Ltd. - Ordinary Shares publicly traded?
Yes, Alpha Tau Medical Ltd. - Ordinary Shares is publicly traded.
What exchange does Alpha Tau Medical Ltd. - Ordinary Shares trade on?
Alpha Tau Medical Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Alpha Tau Medical Ltd. - Ordinary Shares?
The ticker symbol for Alpha Tau Medical Ltd. - Ordinary Shares is DRTS on the Nasdaq Stock Market
What is the current price of Alpha Tau Medical Ltd. - Ordinary Shares?
The current price of Alpha Tau Medical Ltd. - Ordinary Shares is 2.910
When was Alpha Tau Medical Ltd. - Ordinary Shares last traded?
The last trade of Alpha Tau Medical Ltd. - Ordinary Shares was at 06/18/25 03:57 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.